Boston Scientific Corporation announced that it has received FDA approval for its Vercise Gevia deep brain stimulation (DBS) system to be used during full-body MRI scans.
The system was developed for the treatment of patients experiencing symptoms of Parkinson’s disease. It delivers “precisely targeted electrical stimulation” that can help minimize the impact of the disease’s many side effects.
“Boston Scientific continually strives to deliver new solutions that advance the field of neuromodulation and most importantly, result in better outcomes for our patients around the world,” Maulik Nanavaty, senior vice president and president of neuromodulation at Boston Scientific, said in a prepared statement.
“When evaluating which DBS system is best for each of my patients, I always consider the immediate and long term needs my patient might have so that we can effectively address a patient's therapeutic needs even as their disease progresses,” Robert Gross, MD, PhD, of Emory University in Atlanta, said in the same statement. “Customizable therapy, battery life, the size of the device, and access to MRI are factors patients should talk to their doctor about when they are considering deep brain stimulation.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.